STO-3 PUBLICATIONS & ABSTRACTS

Clinical evidence from STO-3


Endocrine publications

Evidence / Endocrine / STO-3

Differential Long-Term Benefit of 2-Year Adjuvant Tamoxifen Therapy for Luminal-Type Breast Cancer: Insights From a 20-Year Follow-Up Analysis of the STO Trials

Publication: ESMO Annals of Oncology, Breast cancer, early stage, Volume 35, Supplement 2S346, September 2024 Authors: M. Rios Romero, O. Danielsson, T. Fornander, A. Nordenskjรถld, G. Pรฉrez Tenorio, N.P. Tobin, B.A. Nordenskjรถld, O. Stรฅl, L. Esserman, L.J. Van't Veer, L.S. Lindstrรถm Title: Differential long-term benefit of 2-year adjuvant tamoxifen Read More

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS:ย  Laura J. Esserman, MD, MBA; Christina Yau, PhD; Carlie K. Thompson, MD; Laura J. van 't Veer, PhD; Alexander D. Borowsky, MD; Katherine A. Hoadley, PhD; Nicholas P. Tobin, PhD; Bo Nordenskjรถld, MD, PhD; Tommy Fornander, MD, PhD; Olle Stรฅl, PhD; Christopher C. Benz, Read More

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Laura J. van โ€˜t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjรถld, Tommy Fornander, Olle Stรฅl, Laura J. Esserman, Linda Sofie Lindstrรถm SUMMARY: 20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients Read More